Eagle Pharmaceuticals, Inc. (EGRX)
NASDAQ: EGRX · IEX Real-Time Price · USD
4.140
+0.070 (1.72%)
At close: Jun 21, 2024, 4:00 PM
4.050
-0.090 (-2.17%)
After-hours: Jun 21, 2024, 5:42 PM EDT

Eagle Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year
20222021202020192018 2017 - 2012
Revenue
316.61171.55187.8195.89213.31
Upgrade
Revenue Growth (YoY)
84.56%-8.66%-4.13%-8.17%-9.88%
Upgrade
Cost of Revenue
94.9442.1845.4760.961.92
Upgrade
Gross Profit
221.67129.37142.34135151.4
Upgrade
Selling, General & Admin
106.6375.3278.676.3760.51
Upgrade
Research & Development
34.0951.2830.7936.8144.42
Upgrade
Other Operating Expenses
000010.62
Upgrade
Operating Expenses
140.71126.6109.38113.18115.54
Upgrade
Operating Income
80.962.7732.9521.8235.85
Upgrade
Interest Expense / Income
4.051.642.582.692.74
Upgrade
Other Expense / Income
15.485.687.7-2.87-0.92
Upgrade
Pretax Income
61.43-4.5522.682234.04
Upgrade
Income Tax
25.794.0810.697.692.14
Upgrade
Net Income
35.64-8.6311.9914.3131.9
Upgrade
Net Income Growth
---16.24%-55.14%-38.58%
Upgrade
Shares Outstanding (Basic)
1313131415
Upgrade
Shares Outstanding (Diluted)
1313141415
Upgrade
Shares Change
0.11%-5.23%-2.60%-7.46%-3.96%
Upgrade
EPS (Basic)
2.76-0.660.891.042.16
Upgrade
EPS (Diluted)
2.73-0.660.871.012.09
Upgrade
EPS Growth
---13.86%-51.67%-36.09%
Upgrade
Free Cash Flow
50.5227.948.7555.2152.25
Upgrade
Free Cash Flow Per Share
3.912.143.624.013.54
Upgrade
Gross Margin
70.01%75.41%75.79%68.91%70.97%
Upgrade
Operating Margin
25.57%1.61%17.55%11.14%16.81%
Upgrade
Profit Margin
11.26%-5.03%6.38%7.31%14.96%
Upgrade
Free Cash Flow Margin
15.96%16.26%25.96%28.18%24.50%
Upgrade
Effective Tax Rate
41.98%-47.13%34.93%6.27%
Upgrade
EBITDA
78.751.8930.0229.3440.44
Upgrade
EBITDA Margin
24.87%1.10%15.98%14.98%18.96%
Upgrade
Depreciation & Amortization
13.274.814.774.653.67
Upgrade
EBIT
65.48-2.9125.2524.6836.77
Upgrade
EBIT Margin
20.68%-1.70%13.45%12.60%17.24%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).